Life Insurance for Cardiomyopathy

Life insurance with cardiomyopathy is absolutely possible — but approvals and pricing depend on the type of cardiomyopathy, how stable the condition has been, and what your most recent cardiac testing shows. Many people assume cardiomyopathy means an automatic decline. In reality, the outcome usually comes down to how the carrier interprets your overall heart function, the risk of progression, whether there have been complications like arrhythmias or hospitalizations, and — most critically — which carrier is reviewing the file. At Diversified Insurance Brokers, we specialize in high-risk life insurance cases involving heart disease, complex diagnoses, and prior declines. We work with a nationwide network of 100+ top-rated carriers and help clients position their medical history correctly from the start — so underwriting sees a clear, accurate, well-documented profile instead of guessing. If you have already been declined, rated higher than expected, or told your case is “too risky,” our job is to identify what triggered that decision and approach carriers that are more realistic for your situation. Cardiomyopathy is not one diagnosis — it is a broad category that can range from mild, stable, and well-managed to more advanced and highly monitored. That is exactly why the same word on two applications can produce very different underwriting outcomes. Some applicants still qualify for traditional term life insurance and select permanent policies, while others may need more specialized options. The key is understanding where your specific case falls before any application is submitted incorrectly.

Life Insurance Quoter

Use the quoter below to get an instant baseline estimate for coverage amounts and term lengths. For cardiomyopathy cases specifically, we then run a separate carrier analysis to identify which insurers evaluate cardiac stability most favorably for your specific type and presentation before any formal application is submitted.

Cardiomyopathy Types — Life Insurance Underwriting Profile

The type of cardiomyopathy matters significantly in underwriting because each variant carries different risk assumptions, different typical complications, and different actuarial trajectories. The table below maps the major cardiomyopathy types to how underwriters typically approach each — and what distinguishes favorable from unfavorable profiles within each type.

General reference only. Actual outcomes depend on full cardiac history, EF stability, complication history, specific carrier guidelines, and documentation quality. Individual results vary significantly within each cardiomyopathy category.

How Cardiomyopathy Is Evaluated for Life Insurance

Life insurance companies underwrite cardiomyopathy with deeper scrutiny than many applicants expect because it can impact long-term heart function and early claim risk. Underwriters do not simply ask “Do you have cardiomyopathy?” They want to know how the condition affects your heart’s performance over time, how stable it has been, and whether it has created risk events like arrhythmias, heart failure symptoms, or recurrent emergency care. From an underwriting perspective, cardiomyopathy is evaluated using a combination of clinical diagnosis details, objective cardiac testing, and stability patterns — which is why some applicants are approved at manageable ratings while others may be postponed or limited to non-traditional options. Underwriters care less about the label on the diagnosis and more about what the condition has done and what it appears likely to do going forward. If you are also navigating other health issues that can compound cardiac risk — like diabetes, sleep apnea, COPD, or prior heart events — carriers typically evaluate the total risk picture, not one diagnosis in isolation. Our resource on life insurance with pre-existing conditions covers how carriers approach this kind of layered risk evaluation.

The Single Most Important Number: Ejection Fraction (EF)

Ejection fraction is one of the most important underwriting metrics for any cardiomyopathy case — it is a standardized, objective measure of how effectively the left ventricle pumps blood, and it gives underwriters a comparable snapshot that can be evaluated across multiple readings over time. EF is reported as a percentage: normal EF is generally 55-70%. Reduced EF (below 40%) signals significant systolic dysfunction. Borderline EF (40-54%) represents a middle zone that is evaluated alongside clinical findings, symptoms, and stability history. The table below maps EF ranges to how underwriters typically interpret them in a cardiomyopathy context.

Why the Cardiomyopathy Type Matters in Underwriting

Cardiomyopathy includes several different conditions that carriers treat very differently. The type helps underwriting estimate how predictable the disease is, what complications are most likely, and what the long-term stability outlook looks like. Dilated cardiomyopathy (DCM) is often evaluated closely for ejection fraction, heart failure symptoms, and the risk of progression — and carriers specifically want to understand whether the DCM has an identifiable and addressable underlying cause. Hypertrophic cardiomyopathy (HCM) is reviewed carefully for the degree of outflow obstruction, family history of sudden cardiac death, any arrhythmia events, and activity restriction requirements — because HCM’s primary underwriting concern is sudden death risk rather than heart failure. Restrictive cardiomyopathy is underwritten conservatively due to functional limitations and systemic disease associations: it often develops in the context of amyloidosis, sarcoidosis, or hemochromatosis, and the systemic disease contributes its own underwriting complexity beyond the cardiac findings alone. Our resource on life insurance for sarcoidosis covers the sarcoidosis underwriting framework that applies when sarcoid-related cardiomyopathy is part of the clinical picture. Arrhythmogenic cardiomyopathy (ARVC/ARVD) is underwritten with the strongest focus on arrhythmia risk and device history — because the primary danger in ARVC is ventricular arrhythmia and sudden cardiac death rather than pump failure.

Underwriters also try to determine whether the cardiomyopathy is linked to a known underlying cause, such as hypertension, coronary disease, viral myocarditis, alcohol-related heart muscle damage, chemotherapy history, or genetic background. These details can materially shift underwriting decisions. Ischemic cardiomyopathy — where the myocardial dysfunction results directly from coronary artery disease and prior heart attacks — requires evaluation of both the ischemic history and the resulting heart function simultaneously. Our resource on life insurance after a heart attack covers the ischemic cardiac underwriting framework in full — the framework that combines with the cardiomyopathy assessment when both are present. For stroke as a cardiac complication — which can occur in DCM through embolic mechanism, particularly in the context of atrial fibrillation — our resource on life insurance after stroke covers how neurological events arising from cardiac causes are evaluated alongside the underlying cardiac history. Peripartum cardiomyopathy and chemotherapy-induced cardiomyopathy represent particularly important subcategories because EF recovery is possible and well-documented — and when EF normalizes and is sustained over time, some carriers will evaluate these cases much more favorably than idiopathic or genetic cardiomyopathy with the same current EF.

NYHA Heart Failure Classification and Its Underwriting Role

The New York Heart Association (NYHA) classification system describes heart failure functional limitation on a four-class scale: Class I (no symptoms with ordinary physical activity), Class II (slight limitation with ordinary activity), Class III (marked limitation — comfortable at rest but symptomatic with less-than-ordinary activity), and Class IV (symptoms at rest or minimal exertion). Life insurance underwriters use NYHA class as a functional assessment alongside the objective EF measurement — because a patient can have a moderately reduced EF but remain functionally Class I with excellent quality of life, or can have the same EF with Class III symptoms indicating significant day-to-day impairment. NYHA Class I and Class II with stable documentation produce meaningfully better underwriting outcomes than Class III or IV regardless of the absolute EF, because functional class directly reflects the insurer’s probability of early claim. A cardiomyopathy case that can document sustained NYHA Class I or Class II over 12-24 months — with cardiology notes confirming this classification — is positioned significantly more favorably than one where functional status is undocumented, variable, or clearly Class III or worse.

Devices (Pacemakers and ICDs) — The Four Questions Underwriters Ask

Many cardiomyopathy cases involve implanted devices such as pacemakers or implantable cardioverter defibrillators (ICDs). Having an ICD does not automatically mean you cannot get coverage, but it changes the underwriting lens substantially. ICDs are implanted specifically because the cardiologist judged the risk of life-threatening ventricular arrhythmia to be high enough to warrant prophylactic treatment — and underwriters take that clinical judgment seriously as an indicator of elevated sudden death risk in the file. The four specific questions underwriters typically ask about any ICD are: first, why was the ICD implanted — was it primary prevention (placed prophylactically due to EF criteria) or secondary prevention (placed after a sustained ventricular arrhythmia event or cardiac arrest)? Second, has the ICD ever fired — if so, how many times, how recently, and what rhythm triggered the shock? Third, has the underlying condition been stable since ICD placement — are there cardiology notes confirming appropriate device function and stable clinical status? Fourth, has EF improved, worsened, or remained stable since the device was placed? Primary prevention ICD placement in a patient who has never had a sustained arrhythmia event and has stable EF since placement is evaluated more favorably than secondary prevention ICD in a patient who has had multiple appropriate shocks for ventricular fibrillation. The difference between these scenarios can be the difference between a table-rated offer at a specialty carrier and a declination across the full traditional market. Understanding how table ratings translate into actual premium cost — including both the table rating mechanism and the flat extra structure some carriers use for cardiac conditions — is essential for evaluating any cardiac underwriting offer. Our resource on what is a flat extra in life insurance covers both mechanisms in the detail needed to evaluate what a rated offer actually costs versus what it provides.

Atrial Fibrillation as a Cardiomyopathy Comorbidity

Atrial fibrillation (AF) is extremely common in cardiomyopathy — both as a consequence of dilated chambers and increased left atrial pressure, and as a cause of tachycardia-induced cardiomyopathy when uncontrolled rapid ventricular response has damaged heart muscle. In underwriting, AF alongside cardiomyopathy creates a compounded assessment: the cardiomyopathy underwriting framework and the arrhythmia underwriting framework are both applied simultaneously, producing a more conservative total risk assumption than either condition would generate alone. Carriers evaluating cardiomyopathy with AF specifically examine whether AF is persistent or paroxysmal, how well the ventricular rate is controlled, whether the patient is on anticoagulation and why, whether any embolic events (stroke or TIA) have occurred, and whether cardioversion or ablation has been attempted or is planned. Patients on anticoagulation for AF-associated cardiomyopathy face the question of why anticoagulation is required — which opens the stroke and thromboembolic risk dimension of the evaluation. When stroke has already occurred as a consequence of AF and cardiomyopathy, our resource on life insurance after stroke covers that specific compounded assessment framework.

Cardiomyopathy With Comorbid Conditions — The Compounded Assessment

Most cardiomyopathy patients have at least one significant comorbid condition that underwriters evaluate alongside the cardiac history. Hypertension is among the most common — and when blood pressure has been the causative or contributing factor in cardiomyopathy, the adequacy of current blood pressure control is heavily weighted in the total risk assessment. Diabetes creates a specific cardiomyopathy pathway (diabetic cardiomyopathy) as well as contributing to the overall cardiovascular risk picture — our resource on life insurance for diabetics with complications covers how diabetic cardiomyopathy and the broader diabetic cardiac complication framework is evaluated when both diagnoses are present. For cardiomyopathy associated with systemic autoimmune disease — including lupus cardiomyopathy, sarcoid cardiomyopathy, and other inflammatory myocardial conditions — the underlying systemic disease adds a separate evaluation dimension. Our resource on life insurance for lupus covers how lupus-related cardiac involvement, including myocarditis and cardiomyopathy, is evaluated when lupus is the underlying diagnosis. HIV-associated cardiomyopathy — a well-documented clinical entity in advanced HIV disease — is covered in the context of our resource on life insurance for HIV/AIDS, where the specific cardiac involvement adds to the comprehensive HIV underwriting picture.

For cardiomyopathy patients seeking life insurance over 50 — the demographic where most acquired cardiomyopathy develops — our resource on life insurance over 50 covers how the age-related underwriting context interacts with chronic cardiac conditions for this population. For applicants who want to understand how annuity income can help fund life insurance premiums without creating household budget strain during a period when cardiac management costs may also be significant, our resource on how annuity payments can fund life insurance premiums covers that financial integration approach. Understanding what standard life insurance policies do not cover — including standard exclusion provisions relevant to cardiac conditions — is covered in our resource on what deaths are not covered by life insurance, which clarifies the exclusion framework that applies regardless of how a policy is rated or issued.

Symptoms, Stability, and Daily Functioning

Beyond test results, carriers evaluate how cardiomyopathy affects daily life. Symptoms like shortness of breath with minimal activity, dizziness, fainting, chest pain, or worsening fatigue raise concerns about progression and future risk — because they indicate that the cardiomyopathy is creating functional limitation that correlates with higher mortality risk. Applicants typically underwrite best when records show minimal or controlled symptoms, no recent ER visits or urgent cardiac events, a stable medication regimen without frequent escalation, and regular cardiology follow-ups with documented compliance. Stability matters as much as severity. A moderately reduced EF that has remained consistent for years with stable notes may underwrite better than a slightly better EF that is declining rapidly or paired with recurrent hospital visits. The story the documentation tells — about a condition being actively managed, monitored, and stable — is what underwriters need to place the case in a favorable risk category rather than defaulting to conservative worst-case assumptions.

Heart Transplant Evaluation — When Cardiomyopathy Has Advanced

For some cardiomyopathy patients with advanced disease, heart transplant evaluation or listing may be part of the clinical picture. Being listed for or having undergone cardiac transplant is one of the most complex underwriting scenarios in the life insurance market. Pre-transplant cardiomyopathy cases that are being evaluated for transplant are typically postponed pending the transplant decision — because underwriting the pre-transplant state produces a risk profile that will change materially at transplant. Post-transplant cardiomyopathy cases are evaluated through the organ transplant underwriting framework, which requires its own stability window, immunosuppressive medication assessment, and rejection history review. Our resource on life insurance for organ transplant recipients covers the post-transplant underwriting framework in detail — including the typical stability windows, documentation requirements, and carrier considerations that apply when cardiac transplant is part of the medical history.

The Prescreening Advantage for Cardiomyopathy Cases

Cardiac underwriting is one of the most technical areas of life insurance — and many agents submit cardiomyopathy cases to one carrier, receive a decline, and stop. That approach fails clients, particularly when there are carriers in the market that may still consider the file with the right presentation. At Diversified Insurance Brokers, we prescreen cardiomyopathy cases, identify carrier fit, and control how the medical history is presented. This helps avoid unnecessary declines and protects future application options. The prescreening process — an informal carrier inquiry before any formal application is submitted — is the protective mechanism that prevents MIB history from accumulating through avoidable declines. Our resource on how to prescreen a life insurance application covers the mechanics of this process. For the accessible no-exam simplified pathway that may be relevant for stable cardiomyopathy cases where traditional full underwriting is not the right initial approach, our resource on no-exam life insurance covers those programs — including when they are and are not realistically accessible for cardiac applicants. For the guaranteed issue fallback that provides coverage regardless of medical history when traditional and simplified underwriting are both unavailable, our resource on guaranteed issue burial insurance covers how graded benefit structures work and when this option makes sense for a cardiomyopathy patient who needs coverage in place now.

What Improves Underwriting Outcomes for Cardiomyopathy

When we help clients improve the probability of an approval and avoid unnecessary declines, we focus on the underwriting drivers that consistently move cases into better categories. The biggest improvements usually come from documenting stability and removing the uncertainty that drives conservative pricing. Stable EF over multiple readings — not just one favorable result — is the single most powerful documentation element for any dilated or ischemic cardiomyopathy case. No recent acute events including ER visits, hospital admissions, or heart failure exacerbations allows underwriting to evaluate the file without the red flag that recent instability creates. Clear cardiology follow-up with documented compliance shows that the condition is being actively monitored and managed — removing the uncertainty that arises when records are sparse or care appears inconsistent. A non-smoker profile and clean tobacco history removes a major compounding cardiovascular risk factor from the total picture. Controlled blood pressure and cholesterol — especially when cardiomyopathy is not progressive — demonstrates that the modifiable cardiovascular risk factors are being addressed alongside the structural cardiac condition. Organization of the medical record presentation also matters: a clean, well-presented file helps underwriting move faster and reduces the chance that the carrier defaults to conservative assumptions due to uncertainty about missing information.

Typical Policy Outcomes We See

There is no “standard” result for cardiomyopathy because the condition spans such a wide range of severity and type. For mild and stable cases — particularly peripartum or chemotherapy-induced cardiomyopathy with normalized EF, or HCM with no obstruction and no arrhythmia history — traditional term life insurance or permanent policies may be available at standard or mild to moderate table ratings. For moderate cardiomyopathy cases with stable EF in the 40-50% range, table-rated offers at specialty carriers that still provide meaningful protection at a workable premium are common. For more advanced or unstable cases — EF below 35%, recent heart failure admissions, ICD with shock history, or declining EF trend — carriers may postpone, decline, or require more time and documentation. In those situations, we explore alternative options such as simplified issue, guaranteed issue, or graded benefit coverage so protection is in place while we work toward future insurability as the stability window extends. No two cardiomyopathy cases are identical — our role is to match your specific medical profile with the carriers most likely to interpret your stability favorably.

Example Case

A 60-year-old non-smoker with dilated cardiomyopathy and an ejection fraction of 45% came to us after being declined by two insurers. He had no recent hospitalizations, consistent cardiology follow-ups, stable medication regimen, and cardiology notes explicitly confirming stable disease status over the prior 18 months. The declines happened because both prior applications went to carriers that use conservative blanket guidelines for any DCM diagnosis regardless of EF range or stability history. By positioning his case with a carrier known for flexibility in moderate cardiac profiles — and ensuring the file clearly communicated the stability history, the EF trend, and the absence of heart failure events — we secured a $250,000, 10-year term policy at a manageable table rating, saving him more than $600 per year compared to the prior offers he had received. The medical reality of his condition had not changed — the carrier selection and documentation presentation changed the outcome.